Jeremy Goldberg
Advisor
jeremy.goldberg@torreyapartners.com
(800) 574-1741
Jeremy is a skilled business development executive with over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. In addition to his work as Advisor at Torreya, he is an advisor to several funds focused on private equity and life sciences investments in the venture and royalty areas. He was a founding partner of ProQuest Investments in 1998, the first cancer-focused venture capital fund, where he and his partners raised over $250 million in Funds I and II to acquire positions in biotechnology, specialty pharmaceutical and medical device companies. Jeremy joined Endo Pharmaceuticals in 2003 as Managing Director, Corporate Development and was responsible for its overall corporate development activities, including structuring, negotiating and closing transactions. Jeremy’s transaction experience includes over 12 product licenses and multi-product license or acquisitions with U.S. and European companies announced while at Endo Pharmaceuticals. Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer, and operating roles at SmithKline and Becton Dickinson. He serves on the Dana Farber Cancer Institute Lank Center Visiting Committee and an NIH-Oxford affiliated board. Jeremy received his A.B. from Harvard College and M.B.A from Harvard Business School.
Copyright © 2010 Torreya Partners LLC. All rights reserved.
Securities offered through Financial West Group, member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities.